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Despite notable advances in the care and survival of preterm infants, a significant proportion 
preterm neonates will have lifelong cognitive, behavioral, and motor and we are still missing 
robustly effective neuroprotective strategies. These therapies must target the 
pathophysiological mechanisms observed in contemporaneous infants and rely on modern 
epidemiology, imaging, and experimental models and assessment techniques. Two drugs, 
magnesium sulfate, and caffeine are already in use in several units, and although their 
targets are apnea of prematurity and myometrial contractility (respectively), they do offer 
improved odds of positive outcomes. Nevertheless, these drugs have limited efficacy, and 
NICU-to-NICU administration varies greatly. As such, there is an obvious need for additional 
specific neurotherapeutic strategies to further enhance the outcome of this very fragile 
population of neonates. The present chapter reviews these issues, highlights bottlenecks that 
need to be solved for meaningful progress in the field, and proposes future innovative 
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1. Pathophysiology of the encephalopathy of prematurity (EP) 
 
It can be estimated that 9 of the 15 million infants born preterm every year (60%) will suffer 
from life-long physical or neurological handicap, largely due to brain injury(1-4). The 
hallmarks of their injury are: hypomyelination, oligodendrocyte maturation arrest, 
axonopathy, neuroinflammation, reduced fractional anisotropy (FA) and cortical volume 
determined by magnetic resonance imaging (MRI), and eventually, significant cognitive 
deficits(5). Collectively the brain damage associated with preterm birth is called the 
Encephalopathy of Prematurity (EP).  Maternal-fetal infection not only precipitates preterm 
birth, but is often clinically silent and a major driver of EP(6). Specifically, a wealth of 
epidemiological and clinical studies have shown that perinatal systemic inflammation, linked 
to chorioamnionitis, funisitis, postnatal sepsis or necrotizing enterocolitis, is a key risk factor 
in developing EP and its associated long-term neurological and behavioral/psychiatric 
deficits, see reviews(7,8). Also, in some cases like placenta abruption or twin-twin 
transfusion, hypoxic-ischemic insult is a notable risk factor (9). Based on animal models of 
white matter damage, chronic hypoxia(10) is also considered another risk factor of EP, but 
conclusive supportive clinical data is still missing and the validity of this concept is 
contested(11). A more convincing argument is that hyperoxia may be involved in the 
pathophysiology of EP(12), as the ex utero environment is relatively high in oxygen 
compared to the in utero environment (13). That hyperoxia plays a role in EP is also 
supported by animal studies(14-16).  
In regards to the severity of injury to the brain, the most recent postmortem neuropathology 
studies (17,18), supported by MRI studies (19), clearly indicate that we have moved, over the 
last two decades, away from typically destructive white matter lesions, the so-called cystic 
periventricular leukomalacia. We have moved towards non-clastic diffuse white matter 
abnormalities, i.e., diffuse white matter injury, on top of which can be superimposed some 
small focal necrotic lesions. Also, MRI studies, have shown abnormal connectivity and 
abnormal grey matter microstructure play an essential role in the long-term deficits (20-23). 
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However, these MRI studies (and all other MRI studies) rely on assumptions of the cellular 
substrate underpinning the imaging signal, and although some work is underway to 
understand this(24), more needs to be done.  Recent unpublished post-mortem studies also 
support the loss of a specific subset of cortical interneurons that play a crucial role in 
neuronal plasticity during development (Stolp & Gressens, unpublished data). This 
observation refines previous post-mortem observations that total proliferation in the 
ganglionic eminence (GE) is reduced in preterm born infants suffering from intra-ventricular 
hemorrahage(25). The sensitivity of interneurons to disruption due to preterm birth relates to 
their on-going migration from the dorsal subventricular zone (SVZ) and GE (ventral SVZ) 
during the third trimester(26). The validity of changes in interneurons has also been pre-
clinically demonstrated in a rabbit model of preterm birth(27) (27). 
 
 
1.1. Neuroinflammation, and microglial activation 
 
Microglia are the innate immune cell of the brain but during development they have critical 
functions in synaptic pruning and as such regulating large scale connectivity(28-30), and 
there are even pro-myelinogenic microglial subtypes(31,32). Microglia share a great deal of 
characteristics with macrophage but numerous cell fate mapping studies have established 
that they are a unique suptype of cell(33,34). Microglia are activated as a consequence of 
systemic inflammation or injury to the brain. Systemic inflammation activates microglia 
indirectly by acting via interleukin-1 (IL-1) receptors on the vast network of endothelial cells 
coating the blood vessels in the brain. IL-1 is an almost ubiquitous cytokine found in the 
blood during infection or injury(35). Activation of these endothelial cell situated receptors 
leads to the production of pro-inflammatory prostaglandins in the parenchyma that activate 
microglia. Microglia are also activated by brain injury, such as hypoxia, or HI, as these events 
lead to cell injury and the release of damage associated messenger proteins (DAMPS) 
and/or the production of toxic metabolites that also active microglia directly(36,37). In vitro, 
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hypoxia and hypoxia have been shown to themselves have a direct effect of microglia, 
including by altering receptor and transcription factor expression(38-40).  The activation of 
microglia, is a general term to describe a disruption away from their typically homeostatic 
roles in brain development, maintenance and surveying. We characterize the activation state 
of microglial based on their expression of receptors, enzymes and functions such as 
phagocytosis, that altogether give us clues as to the overall effect of the cell on the brain, or 
invading pathogen. Activation can take a number of forms, and in paradigms of brain injury, 
we need to create simplified nomenclature, but in reality, cells can transition between 
activation states and express markers of multiple states. The general activation states of 
microglia include a M1-like classically pro-inflammatory state, M2a classically anti-
inflammatory or regenerative state and M2b immune-regulatory activation profile(41). Of 
note, microglia activated to a pro-inflammatory state generate pro-inflammatory cytokines 
and reactive oxygen species (Figure 1). Numerous in vitro systems and in vivo models of EP 
have shown that microglial activation can lead to oligodendrocyte precursor (OPC) blockade 
or death and subsequent myelin deficit (please see next section) (10,42-44). In addition, 
activated microglia will lose their normal functions in synapse development, function, and 
plasticity, having potentially a detrimental effect on neuronal differentiation and connectivity. 
This double hit (production of toxic factors for neighboring neural cells and loss of normal 
microglial functions to shape axonal connectivity and synaptic elimination/function) has 
emerged recently as one key hallmark of EP.  
 
 
1.2. Oligodendrocyte precursor cell maturation blockade and dysmyelination 
The latest neuropathological studies have shown that, except in the most severe cases of EP 
that OPC maturation blockade rather than OPC death was the key feature of diffuse white 
matter injury (17,18). For excellent reviews including oligodendrocyte maturation in the 
context of perinatal brain injury please refer to (45,46). One has to remember that preterm 
infants who die are generally at the most severe end of the spectrum, and postmortem 
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studies are potentially biased by the local standards for clinical care and the local ethical 
basis for withdrawing care. As such, when studying neuropathological events with the aim of 
designing neurotherapies that the target is indeed the majority of preterm born infants survive 
the perinatal period.  Similarly to the human condition, in animal models, moderate systemic 
inflammation leads to OPC blockade and hypomyelination (44,47). Moderate inflammation is 
used to model the great number of preterm born infants born suffering a sub-clinical level of 
infection but who are still at a higher risk of EP and poor outcomes(48,49). While more 
severe insult models (i.e., severe systemic inflammation, protracted hypoxia or hypoxic-
ischemic insult) lead to a combination of OPC death followed by proliferation of OPCs and 
maturation blockade of these newly formed cells (10,44,50).  
The mechanisms by which OPC maturation is blocked center on responses to the 
neuroinflammatory milieu, for a full review see(51). It has been demonstrated in animal 
models that OPC maturation blockade is caused by exposure to inflammatory prostaglandins 
(52), soluble factors called Wnts(53) and extracellular matrix proteins, the hyalurans, via their 
activation of damage associated protein receptors (54). 
In all rodent models that we have seen, over time (at a time-point equivalent to young 
adulthood or late puberty) the deficits in OPC maturation/myelination resolve themselves for 
reasons in part linked to the naturally higher rate of turnover of OPC in rodents compared to 
humans (55). The human brain exchanges roughly 0.3% oligodendrocytes per year in 
adulthood, but the mouse exchanges approximately 10-30 times that number; 1-3% 
oligodendrocytes per year(56). However, despite this normalization of myelination levels, 
behavioral impairments do persist in rodent models well into adulthood. In humans, long-term 
MRI studies indicate that abnormalities in structure of the white and grey matter persist well 
into adulthood(57-59). Histological correlates of these are almost impossible to study as most 
preterm born infants without substantial gross motor impairments, and as such co-morbidities 
such as epilepsy, live to a close to normal age. As such, preterm born infants born into the 




1.3. Specific deficits in interneuron subtypes  
 
Preliminary postmortem and experimental studies suggest some specific deficits of some 
subsets of interneurons at least in the cortex, as outlined above. Interneurons play a key role 
in the balance between excitation and inhibition. In addition, some interneurons like 
parvalbumin interneurons are instrumental for neuronal circuit plasticity (60), and recent 
studies suggest that this specific subset of interneurons is decreased in the cortex of preterm 
infants. The underlying mechanism, possibly reduced production, abnormal migration, 
reduced survival, lack of differentiation, is unknown.  However, in preterm born infants 
suffering from an intra-ventricular hemorrhage, proliferation within the region of the brain 
responsible for the production of interneurons, the ganglionic emminance, is reduced(25). 
Studies in humans are time consuming as the vast majority of the brain needs to be mapped 
in many infants to determine the nature of a numerical or migration change. 
 
 
1.4. Impaired connectivity, neuronal differentiation, synaptogenesis 
Almost all of the data available on grey matter changes in EP are from imaging studies, or 
from animal models. Imaging studies have focused on microstructural alterations, and have 
begun to apply complex models derived from developmental data and our general 
understanding of brain development (23,61). However, a limitation of these models is a lack 
of specificity between MRI signal and neuropathological substrate, as illustrated in a recent 
paper using a technique where the hippocampus was assessed with high field MRI and also 
subjected to immunohistological analysis and detailed co-registration(24). Of interest, this 
study found that fractional anisotropy correlated with astrocyte density a cell types typically 
not considered in MRI studies. Further studies will be necessary to determine the precise 
cellular and molecular substratum of abnormal connectivity and grey matter microstructure 
observed on MRI. Large animal models of severe EP, have illustrated that grey matter 
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deficits include changes in dendritic arborisation in subplate neurons (62) and also impaired 




1.5. Tertiary phase 
 
Many months and years after injury to the immature brain there may be persisting injury 
processes, in addition to developmental disruption associated with the initial brain insult (64). 
These tertiary mechanisms of damage might include persistent inflammation and altered 
epigenetics and are implicit in preventing endogenous repair and regeneration, predisposing 
to development of later cognitive dysfunction and sensitization to further injury (Figure 2). 
Tertiary mechanisms of damage might be treatable, including by preventing the repressive 
effects of microglial and astrocyte over activation, recapitulating developmentally permissive 
epigenetic conditions, and using cell therapies to stimulate repair and regeneration. 
Recognizing tertiary mechanisms of damage might be the first step in a complex translational 
task to tailor safe and effective therapies that can be applied to the already developmentally 
disrupted brain long after an insult.  Clinical data accumulates that the tertiary phase of injury 
can be observed. Initially, positron emission spectroscopy demonstrated that many years 
after an adult TBI that the human adult brain had on-going glial reacvitiy (65). More recently, 
Evidence for tertiary phase proceses after PBI includes (i) abnormal cortical metabolite levels 
detected by MR spectroscopy (MRS) at 1 yr of age after hypoxia-ischemia at term birth(66), 
and in adults who were born preterm(67), and (ii) increased serum pro-inflammatory 
cytokines and heightened responses to endotoxin re-challenge in 7 yr old children with 
cerebral palsy after preterm birth(68).  Consistent with these chemical changes are the 
clinical observations that cerebral palsy, a severe complication following perinatal brain 
injury, is an independent risk factor for adult stroke(69); that preterm birth is a risk factor for 
dementia-associated neurocognitive impairments(70) and neuropsychiatric disorders such as 
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depression in later life(71). Indeed, for those born preterm, health and social status deficits 
are greater in the 4th decade compared with the 2nd decade of life(72). Furthermore, 
experimental studies also show that early life exposure to inflammation can predispose to 
later increased brain injury severity, and even increase the severity of alzheimers disease or 
multiple sclerosis(73-76). The chief candidate for mediating these effects are microglia. Of 
note, microglia are long-lived, in the human brain this is estimated to be up to 20 years and in 
the mouse for their entire lives(77,78). After brain injury microglia number and function is 
altered for many months and even years in humans(65) and non-human primates(79), and 
into adulthood in experimental models of perinatal brain injury(73,80-82). Work to link the 
imaging data and serum biomarkers indicating tertiary phase changes with neuropathological 
changes that are viable neurotherapeutic targets is still underway. However, we speculate 
that anti-inflammatory drugs with good tolerability administered over long periods of time 
might be capable of incremental improvements in neurological outcomes for people suffering 
the consequences of EP.  
 
 
2. Current therapies, recent and ongoing clinical trials 
 
Neuroprotection of the preterm brain is a health care priority both in terms of suffering and 
economy. However, the commitment of drug makers within the field of perinatal 
neuroprotection remains scarce despite positive measures put into place by the EMA and the 
TGA to support paediatric drug development. What are the potential reasons for this lack of 
investment? i) Perinatal neuroprotection does not represent a big financial market with 
relatively few patients treated once for a few days or a few weeks; ii) pharmacokinetics, 
metabolism, interactions with other drugs, and potential side effects are poorly understood in 
new-borns and might change with gestational age at birth; this combined with the fact that 
new-borns (and especially very preterm new-borns) are fragile potentially increases the risk 
for adverse outcomes in clinical trials, which could lead to legal procedures and have a very 
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negative impact for the reputation of the drug company in the general public; iii) drugs may 
leave markers in development which are not necessarily due to the drug, but due to the 
combination of the reduced lesion and the development stage, and these markers may 
appear in cohorts; thus there is the possibility of adolescents suing drug makers, where their 
lives have been saved, but certain developmental markers remain which might be, rightly or 
wrongly, ascribed to the drug. For these types of reasons, the pharmaceutical industry is 
reluctant to engage in this area. In this context, academic laboratories, in most instances, do 
not have the capacity to develop new drugs for a given indication. Therefore, re-purposing 
existing drugs is most likely the shortest way to improve the outcome of preterm infants in the 
coming years.  
 
 
2.1. Magnesium sulfate 
 
There have been controversies related to the use of this magnesium sulfate, due to a 
conflagration of issues such as unrelated case reports and biased opinion publications. 
Nevertheless, numerous RCTs have tested the efficacy of magnesium sulfate given to 
mothers at risk to deliver prematurely throughout the world during the last decade. Although 
the number of included patients in some trials was not sufficient to reach significance, all 
trials showed the same tendency for neuroprotection. A recent meta-analysis (83) of five 
randomized trials, including a total of 5,493 women and 6,131 babies, unambiguously shows 
that antenatal magnesium sulfate given prior to preterm birth reduces motor problems (CP) 
and reduces the combined risk of fetal/infant death or CP. Although the effect sizes are not 
large they still significant, and the authors rightly state that “widespread adoption worldwide 
of this relatively inexpensive, easy-to-administer treatment would lead to important global 
health benefits for infants born preterm” (83,84). This positive endorsement for magnesium 
sulfate as a neuroprotectant is also found in a 2009 Cochrane review (85) and in scientific 







Caffeine is a xanthine that is used in centers all over the world to prevent and treat apneas of 
prematurity due to its action to stimulate the central nervous system and respiratory muscle 
function. Through its nonselective antagonist effects on adenosine receptors (AR), caffeine 
also has potentially multiple impacts on the developing brain of a preterm infant(87). This 
includes effects to induce the precocial maturation of oligodendrocytes, which if stimulated 
too early in development could reduce the pool of oligodendrocytes present to produce 
myelin in later life.  In addition to AR antagonism, caffeine has other biological actions, 
including inhibiting phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promoting 
calcium release from intracellular stores, and interfering with GABA-A receptors. 
Human studies have shown that caffeine significantly reduced motor deficits in preterm 
infants without impacting negatively on their cognitive outcome at 11 years of age (88). 
Increasing the doses of caffeine would be tempting to potentially further increase the 
neuroprotective effects. However, we should keep in mind that adenosine receptors are 
highly expressed in the developing brain and are playing important modulating roles(89). 
RCTs seem the only way to address this issue.  For a discussion of the issues surrounding 
providing care in the NICU and off target effects of drugs (and their excipients) we point the 
reader to an aging, but still pertinent review(90). 
 
 
2.3. Erythropoietin (EPO) 
 
Erythropoietin (EPO) has been used safely for decades in preterm infants to reduce the 
necessity for blood transfusions. EPO also has neuroprotective effects in animal models of 
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term brain injury and some immature paradigms(91-94), although at higher doses as the 
blood-brain barrier penetrance is not optimal. A RCT with EPO given after preterm birth has 
been conducted in Switzerland. The MRI evaluation of brain lesions at term corrected age in 
a subset of patients showed a significant decrease of the lesion burden in the EPO arm (95). 
However, the 2-year age neurodevelopmental evaluation on the whole cohort failed to show 
any significant benefit (96). In parallel, a large-scale trial has been initiated, the PEANUT 
trial, into which 940 patients will be enrolled at 19 sites across the United States in order to 
evaluate 752 infants at 22–26 months corrected age (97). Although the safety of EPO is well 
established and the idea of re-purposing this drug as a neuroprotectant is valid, one has to 
stress that there is no pre-clinical data showing the neuroprotective effects of EPO in a 
model of EP, involving the contemporaneous constellation features of EP. This raises 
questions about whether we are still best placed to understand the best paradigm to delivery 





Melatonin is very safe including at very high doses in preterm infants (98) and its 
pharmacokinetics has been established in very preterm infants (99). Melatonin has multiple 
protective effects including anti-oxidant, trophic, anti-apoptotic, mitochondria-protective, and 
anti-inflammatory effects (98,100). In addition, preterm infants are not able to produce their 
own melatonin and, while losing their maternal daily supply, are deprived of melatonin when 
compared to age-matched fetuses. Clinical trials are ongoing exploring the optimal dose and 
timing (pre- vs post-natal or combination of both) of exposure. However, these studies are 
facing the issue of formulation, specifically, that melatonin is very difficult to dissolve, 
especially in a small volume compatible with a tiny preterm neonate. It is currently formulated 
with ethanol as an excipient although companies working on improved formulation. However, 
we do with to highlight that many drugs used in the NICU are dissolved in ethanol, and other 
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compounds considered toxic to the developing brain(101-103). Perhaps melatonin in its 
current form is a viable neurotherapeutic, if we were better able to stratify patients at the 
highest risk of EP and long term functional injury and for whom the risk-benefit ratio was 
sufficiently well balanced (see, Stratification section belwo).   
 
2.5. Breast milk 
 
Neuroprotection can be based on therapies that need to be FDA and EMA approved, such 
as magnesium sulfate, on limiting toxic environment, for example choosing the right steroid 
for lungs, such as hydrocortisone vs dexamethasone, or by changing our non-treatment 
realted practices. In this regard, “predominant breast milk feeding” in the first 28 days of life 
was associated with a greater deep nuclear gray matter volume at term equivalent age and 
better IQ, academic achievement, working memory, and motor function at 7 years of age in 
very preterm infants” (104), demonstrating that we have the ability to implement a therapy, 
with no side effect at all, that is a key step forward protecting the brain of preterm infants. 
Difficulties in implementing breast milk feeding in the NICU include maternal poor health and 
stress due to the preterm delivery, social factors related to the lower than optimal rates of 
breastfeeding the general community, and linked to this poor access to lactation support 
within the hospital. Milk banks providing donated milk to infants has had some success, and 
although these endeavors are expensive they are likely no more so than poor infant 
outcomes, or novel therapy design.  
 
 
3. Future directions 
 
3.1. Early vs delayed intervention and need for stratifications through biomarkers 
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Obviously, the earlier one could intervene in a pathological process, the more chance to 
block or slow down it and prevent subsequent long-term consequences. At the beginning of 
the 21st century, this universal truism still faces major limitations in the field of 
neuroprotection of preterm neonates. First, very and extremely preterm neonates are 
extremely fragile facing the extreme immaturity of all their organs making the encounter with 
the ex-utero and NICU environment very challenging. Any additional therapeutic intervention 
is always a risk factor to further jeopardize their precarious homeostatic situation. Second, 
within the population of very and extremely preterm neonates, despite the risk of long term 
consequences, a significant number of them will do well. These two facts have major 
implications in terms of neuroprotection of preterm infants. Two complementary avenues of 
research could help to resolve this low sensitivity/specificity of current prediction paradigms. 
One would be to delay interventions (based on the tertiary phase concept that opens up a 
much larger window for intervention) and only treat infants with clearly identified 
abnormalities or major risk factors (such as signs on sophisticated MRI) of adverse outcome. 
In this context, one has to keep in mind that for some neurodevelopmental processes, timing 
is particularly important. For example, restoring myelination at a distant step from normal 
timing might not be sufficient to restore the function. The alternative approach would be to 
identify very early (first hours/days of life) sensitive and specific biomarkers of negative 
outcome. These latter could include a combination of blood/urine-derived markers based on 
Omics studies on circulating blood cells (i.e. micro-RNAs, mRNA, proteins, metabolic 
markers) and SNPs, imaging being performed at bedside such as ultrafast Doppler and 
related techniques.  (105). 
 
In the hunt for biomarkers for outcome recently, an integrative analysis of data from an 
animal model of EP together with human genomics data (SNPs associated with white matter 
abnormalities on MRI) has allowed the identification of potential molecular targets relevant to 
preterm infant brain injury and also predisposing infants to poorer outcomes(106,107). 
Genomics-imaging studies of this type have identified SNPs in fatty acid metabolism(108), 
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the transcriptional regulator PPARg(107,109), and in Wnt pathway(110), which in the future 
may provide us the ability to screen for specific genotypes as risk stratification guides.  
 
 
3.2. Improving outcome measurements 
 
The efficacy and importantly the true safely of a strategy can only be judged over a long 
period of time, and definite outcome of interventions in preterm infants require at least 6-10 
years for every clinical trial. If the rate of attrition of clinical trials for preterm birth is 
comparable to a disease like Alzheimer disease, several decades at least might be 
necessary, unless luck is on our side, to uncover a new additive protective strategy. Although 
long-term RCT will remain the gold standard, trials based on early proxies, like for example 
sophisticated MRI at term corrected age on smaller samples might serve as a “triage” 
pipeline to select the best candidates for future classical RCTs.  As an example of this 
approach we would like to highlight a study conducted by the team at the Center for the 
Developing brain at King’s College London (KCL). They validated across cohorts of term 
born infants diagnosed with encephalopathy related to hypoxia-ischemia (HIE) that a positive 
outcome could be reasonably predicted by a reduction in lactate to N-acetyl aspartate ratio in 
the thalamus and in preserved fractional anisotropy in the posterior limb of the internal 
capsule (PLIC), measured with magnetic resonance spectroscopy and MRI, respectively, 
measured within 15 days of birth (111).Using these short outcome measures they were able 
to disprove the hypothesis that inhaled Xenon would be a viable adjunct therapy for 
hypothermia which is the standard of care for term born infants with HIE, but that has a 
limited efficacy. The team from the Centre for the Developing Brain at KCL have tested the 
sensitivity of Tract-Based Spatial Statistics (TBSS) to a simulated treatment effect in preterm 
neonates successfully, but this has not yet been applied to a patient cohort (22) As such, 
currently the first robust outcome data is available only at 2 years of age for preterm born 
infants. Imaging modalities have become better at measuring micro-structural abnormalities 
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(112,113) despite our limited understanding of the specific cellular nature of the signals(24) 
and that once a clinical trial is put into place in this center that the usefulness of TBSS as a 
proxy can be properly tested. 
 
 
3.3. Manipulating the inflammatory milieu 
As described above microglia play a substantial role in the neuroinflammatory processes 
leading to EP and these cells can display phenotypes with diverse functions including pro-
inflammatory or toxic, anti-inflammatory or immunomodulatory, pro-repair or pro-plasticity, 
plus other emerging phenotypes(32,114). In this context, blocking the activity of all microglia 
can be deleterious as shown in models of term infant HI injury (115) and also adult HI 
injury(116). The difficulty in pan-supression of inflammation can also be illustrated in the 
history of minocycline treatment for the disease ALS, amyloid lateral sclerosis. Although 
inflammation is considered central to the neuropathology of this disease treatment with the 
broad anti-inflammatory minocycline excascerbated patient symptoms (117).  
 
Astrocytes also play a key role in neuroinflammatory reactions, although their specific role 
has not been heavily studied in preterm infant post-mortem tissues. It has been shown 
previously that there is a gestational age dependent activation of astrocytes associated with 
white matter injury, where in very preterm born infant brain (i.e., 24-29 weeks gestational 
age) there is no astrogliosis, but astrogliosis is present in infants classified as preterm (i.e., 
30-34 weeks gestational age)(118). Astrocytes have also been classified into the subtypes, 
the A1 neurotoxic and A2 regenerative subtypes based on their expression of receptors, 
cytokines, chemokines and enzymes(119-121). Although these phenotypes are less studied 
than microglia and in particular how they relate to the developing brain is poorly understood. 
Currently little is known about how to target astrocytes specifically to reduce EP, but 
experimental evidence suggests a cross talk between microglia and A2-associated astrocyte 
mediated by the prostaglandin COX2 is involved in EP(52). Targeting COX2 production 
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globally with nimesulide in this paradigm proved to be neuroprotective against EP. However, 
the nimesulide treatment of non-injured mice in this model part of a set of controls, caused 
hypermyelination, highlighting that processes generally classified as inflammatory have in 
normal brain development and towards the need for robust treatment criteria. 
 
A recent study has provided for the first time in a large animal model of the preterm infant 
exposed to an endotoxin (i.e. chorioamnionitis), data on the effect on the brain and systemic 
inflammatory markers over a long period – a total of 8 days. It is possible to identify two 
waves of changes in response to endotoxin exposure, including in systemic inflammatory 
mediators and neuronal architecture(51).  As such, without clear biomarkers for the stage 
and severity of inflammation (including the states of microglia and astroglial activation) we 




3.4. Oxidative stress 
 
Although targeting reactive oxygen stress has been a failure in most clinical trials for a large 
number of disorders, the use of safe anti-oxidants in combination with other drugs targeting 
other cell processes might have and added value. Allopurinol, N-acetyl-cysteine, curcumin, 
and other molecules could belong to this category (122,123). We believe that increasing 
information about the necessary role of classically pro-inflammatory microglia to lessen injury 
volumes, perhaps by setting up the repair and regeneration phases (as outlined above) in the 
acute phase of injury explains the failures of anti-ROS therapies.  
 
 
3.5. OPC maturation 
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Acting directly on OPC to promote their maturation is an obvious strategy. Basic 
neuroscience has taught us a lot on the molecular mechanisms controlling the different steps 
of maturation of OPCs to reach a fully mature oligodendrocyte stage that is able to produce 
myelin. In addition, the field of multiple sclerosis (MS) is facing a somewhat similar issue with 
some newly formed OPCs failing to mature and to repair the demyelinating lesion. Based on 
the fact that preterm infants are somewhat deprived of thyroid hormones that are important 
for OPC maturation, a supplementation of T3/T4 has been suggested. However, animal 
models have shown a failure of T3/T4 to improve the myelin status (124,125). Targets 
identified in MS animal models and currently tested in clinical trials include histamine-3 
receptor(126) that was recently shown to be neuroprotective as well in a model of EP 
(Gressens and Chuang, unpublished data). 
 
 
3.6. Connectivity and interneurons 
 
As mentioned above, despite the fact that grey matter abnormalities might play a very 
important role in the long-term consequences of prematurity, there is not currently enough 
knowledge to make any specific hypotheses on the potential targets for neuroprotection. 
Generally, these are likely to focus on cell specific delivery of drugs that can reactivate earlier 
developmental programs to support integration steps that may be been disrupted, especially 
for interneuons. Also, more speculatively, we know that microglia are responsible for 
manipulating the connectome throughout life (28,29,127) and we know that microglial 
functions remain altered for many months if not years after brain injury(64,65). Taking these 
two facts together, we can assume that in the future, cell specific manipulation of microglial 
functions will give us the ability to enhance the beneficial effects of physical and cognitive 




3.7. Stem cells and microvesicles 
 
In term infants with neonatal encephalopathy, mesenchymal stem cells (MSCs) appear at 
this stage as the most promising stem cells for therapy. MSCs have anti-inflammatory and 
pro-repair effects and stimulate the production and survival of endogenous stem cells (128). 
In addition, in rodents and non-human primates they can reach the damaged brain when 
administered intra-nasally. Of note, at least in cell culture, they release a significant amount 
of microvesicles that contain numerous types of biological materials (lipids, enzymes, mRNA, 
micro-RNAs, …) that can cross-talk with other cell types and that might mediate some of the 
positive effects of MSCs (129). The safety of MScs in preterm infants is totally unknown. In 
this context, after having solved the issues of timing and single vs repeated administrations, 
route of administration, doses, and optimal type of MSCs, the safest place to start might be in 
a delayed manner in infants where abnormalities have been confirmed.  
 
 
3.8. Nanoparticles and cell-specific targeting 
 
Especially during normal brain development, different cells types use similar pathways, 
sometimes with antithetical effects (for example, OPCs shut down Wnt pathway to mature 
while Wnt pathway shut down in microglia promotes their toxicity). Therefore, being able to 
target specifically one cell type could increase efficacy while limiting side effects. Engineered 
nanoparticles used as carrier for therapeutics might help to improve cell specificity (123). 
Evidently, efficacy and safety (in particular lack of long-term accumulation in the brain and 
organism) of these nanoparticles has to be validated in the first place. 
 
3.9 Harnessing the power of pretreatment 
Two recent studies have provided a possibly revolutionary tool to the field of preterm infant 
care; a non-invasive test that can predict preterm delivery. In the first study of 400 
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women(130), a blood test taken at 15 to 20 weeks gestation was able to predict 80.3% of 
women who went on to have any preterm birth using a matrix of values from 25 variables in 
the blood. Importantly, it had a 95% predictive ability for women who would give birth before 
32 weeks due to pre-eclampsia. The second smaller study undertook to develop a test for 
measuring gestational age and for predicting preterm birth(131). Firstly, they found that with 
a combination of 7 cell free RNAs from the blood they could predict gestational age with the 
same accuracy as a first trimester ultrasound. Second, also using a battery of cell free RNA 
markers they were able to predict preterm birth in a high risk cohort more than 2 months 
before delivery. It is worth noting that both of these studies will require extensive cross-cohort 
validation, but they are exciting advances in our field.  
 
 
Although for some time now, in high risk women, cervical length and cervical fetal fibronectin 
length have had strong predictive values for imminent delivery(132). However this testing is 
not effective for low risk women(133). In addition, multi-modal screening tools have been 
designed that have excellent specificity and sensitivity, but these also rely on multiple 
invasive procedures and have lesser efficacy in low risk populations(134). The importance of 
identifying women who will go on to deliver preterm cannot be understated as preventing 
rather than treating an injury is always the preferred approach. It’s importance is underscored 
by the fact that a small study has shown using fetal MRI, that functional connectivity in the 
fetal brain is already decreased before  a pre-term delivery(135). The authors state that ‘first 
human data to suggest that disabilities frequently accompanying extreme prematurity, such 
as autism and ADHD, may derive from pre-existing intrauterine neurological conditions, 
especially given that these disorders have neuroconnectional bases’. Together with an ability 
to determine which babies will be born early, in depth fetal imaging will undoubtedly provide 
more information regarding what the initial triggers for preterm birth are and as such, 





Despite significant improvement of survival and outcome over the last decades, a significant 
proportion premature infants have long-term cognitive and behavioral deficits. The search for 
efficient and safe neuroprotective strategies for this high-risk population remains a heath 
care priority. Novel targets and candidate drugs have been proposed. To maximize the 
chance of conclusive RCTs, it seems necessary to have solid preclinical data, a good design 





The authors’ research is funded by the Wellcome Trust (WT094823), Inserm, Université 
Paris Diderot, Fondation Leducq (DSRR_P34404), Fondation Grace de Monaco, Fondation 
Roger de Spoelberch, PremUP, Fondation des Gueules Cassées, and an additional grant 
from “Investissement d'Avenir -ANR-11-INBS-0011-“ NeurATRIS. The authors acknowledge 
financial support from the Department of Health via the National Institute for Health Research 
(NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS 
Foundation Trust in partnership with King's College London and King’s College Hospital NHS 
Foundation Trust. The supporting bodies played no role in any aspect of study design, 




6. Legends of Figures 
 
Figure 1. Schematic representation of the pathophysiology of EP induced by inflammation.  
 
Figure 2. Outline of the acute, secondary, and tertiary damage phases in the EP (adapted 
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